Evidence map›Paper›PMID 41888797›Full record

ReviewMolecular cancer2026

Cuproptosis in inflammation and cancer: molecular mechanisms and therapeutic targets.

Jingwen Liu, Hairuo Huang, Peng Luo, Yang Shen, Shurong Hu, Xiaojun Zhang, Qiao Yu, Yanshan Liu, Letong Huang, Jinhua Luo and 4 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jingwen Liu *Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Hairuo Huang *China Medical University, Shenyang, 110122, China.
Peng Luo *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510000, China.
Yang ShenDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shurong HuDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Xiaojun ZhangDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Qiao YuDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Yanshan LiuBasic and Translational Research Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Letong HuangZunyi Medical University, Zunyi, 563000, China.
Jinhua LuoThe Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
Yuxuan ZhuDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR, 999077, People's Republic of China. jonaszhu@cityu.edu.cn.
Qianqian ZhaoDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zhao.qianqian1@zs-hospital.sh.cn.
Deming JiangLaboratory Animal Center, Zhejiang University, Hangzhou, 310009, China. gemnjiang@zju.edu.cn.
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200000, China. tangbufu@zju.edu.cn.

Funding

Natural Science Foundation of Zhejiang Province LQN26H160014
6 · The paper itself

Abstract

Cellular processes depend on Copper(Cu) homeostasis, but overload of Cu in cells leads to the disruption of that balance and induces a specialized model of regulated cell death known as cuproptosis. As opposed to the conventional cell death modalities, this mechanism features the connection of Cu ions with fatty-acylated elements of the TCA cycle, which subsequently promotes proteotoxic clustering and dysfunction of the mitochondria. Cuproptosis has a distinct and regulated pathway that is not responsive to standard cell demise inhibitors, which warrant its potential role in a number of pathophysiological mechanisms, specifically in the pathogenesis of inflammatory conditions and cancer. However, the disease-specific regulatory networks of its functioning cannot be comprehensively studied, and it has been a great challenge in regard to designing specific therapeutic developments. This paper critically analyzes the regulatory processes of copper equilibrium and cuproptosis, focusing on the important regulatory genes and their interaction networks. We describe pathological implications of cuproptosis in inflammation and malignancies, outline the recent intervention methods, and address the limitations of the current research such as lack of in vivo models and biomarkers. Not only do we offer a systematic source of information about biological importance of cuproptosis but also suggest novel knowledge about the specific treatment of inflammation and cancer which has a great theoretical value and promising opportunities of its practical implementation.

Indexed as

CopperCuproptosisInflammationNeoplasmsAnimalsHomeostasisHumansMolecular Targeted TherapyCopperCancerClinical applicationCuproptosis,Copper homeostasisInflammatory diseasesTargeted therapy

Identifiers

PMID41888797
PMCPMC13141643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.